Investigation of synergistic effects of Myc decoy oligodeoxynucleotide loaded in selenium nanostructures and chemoradiotherapy in prostate cancer cell

Introduction: MYC gene is considered as important oncogene in many cancers. Transcription factor decoy oligodeoxynucleotide (TFD) strategy as a new ODN-based therapeutic modality holds promise for cancer treatment. Selenium nanostructures have attracted more and more attention for their higher anticancer efficacy. In the present study, we investigated the synergistic effects of MYC decoy oligodeoxynucleotides-loaded Selenium nanocarriers on X‐irradiation exposure as a combinational therapy on LNCap prostate cancer cells.Materials and Methods: MYC decoy ODNs designed based on Bcl-۲ gene promoter and synthesized. After synthesis of SeNP@BSA-Chi-MTX, decoy ODNs loaded on nanostructure. Then, physicochemical characteristics and in vitro effects of SeNP@BSA-DEC-Chi-MTX (as final formulation) compared to other groups in both conditions (with and without radiation exposure) by uptake, MTT, cell cycle, apoptosis, and tumorsphere assays were investigated on the LNCaP cell line.Results: Our results revealed that the stable SeNps was successfully synthesized. The ODNs release from the Selenium nanocarrier system exhibited controlled and pH-dependent behavior as the best models to explain the ODN release profile. The final formulation of nanostructure was efficiently taken up by LNCap cells and significantly inhibited cell growth and increased apoptosis rate in without radiation exposure conditions. The synergistic effect of Final formulation of nanostructure with X-irradiation showed that more cell growth inhibition, apoptosis induction, cell cycle arrest, and migration reduction of LNCap cells compared to without radiation exposure condition.Conclusion: SeNP@BSA-DEC-Chi-MTX can potentially suppress the cancerous properties of LNCap cells and the presented nanocarrier system can be a promising approach for targeted gene delivery in cancer treatment.

Keywords:

Prostate Cancer , TFD , SeNps , Combination therapy , MYC transcription factor